Research highlights and advances at the 2019 Myasthenia Gravis Foundation of America Scientific Session
10.3760/cma.j.cn113694-20201029-00821
- VernacularTitle:2019年美国重症肌无力基金会科学会议研究热点和进展
- Author:
Hao RAN
;
Weibin LIU
- From:
Chinese Journal of Neurology
2021;54(5):532-534
- CountryChina
- Language:Chinese
-
Abstract:
The main content of the 2019 Myasthenia Gravis Foundation of America Scientific Session is summarized, and the main conclusions are presented as follows: Muscle-specific receptor tyrosine kinases antibody positive myasthenia gravis (MuSK-MG) is still the research hot spot in MG research fields, including the clinical researches, the clinical pharmaceutical researches and the fundamental experiment researches. Thymectomy shows safety and effectiveness for acetycholine receptor antibody positive MG (AChR-MG). However, thymectomy needs further discussion about the safety and effectiveness for other types of MG. AChR-MG patients with or without thymoma can benefit from thymectomy. Now there are still no special effective drugs to cure MG, and monoclonal antibody drugs are the hopes for MG patients. With the emergence of different kinds of monoclonal antibodies, MG will be more likely to be conquered. More attention has been paid to the role of B cells′ origin and apoptosis abnormality in the pathogenesis of MG in MG researches.
